Failed IVF and a Second Medical Opinion: What to Do Next

Medically reviewed on 22 August 2026 - Dr. Senai Aksoy
A thoughtful medical consultation discussing embryology records and second opinion options after a failed IVF cycle

Key Takeaways

A failed IVF cycle is not a dead end — it is clinical information that can help guide a structured review. A meaningful second opinion starts with obtaining the records held about your care, including stimulation, embryology, and transfer reports. ESHRE recommends an individualised approach to recurrent implantation failure, while ASRM's 2026 opinion uses an estimated 95% cumulative chance of a positive pregnancy test rather than a fixed cycle count. In Turkey, Article 16 allows patients to inspect and obtain a copy of records containing information about their health.

Key evidence: ASRM Practice Committee — Recurrent Implantation Failure Opinion (2026) ESHRE Guidelines — Recurrent Implantation Failure Almohammadi et al. — Interventions for Recurrent Implantation Failure (2025)

A failed IVF cycle is never a neutral event. It affects a couple’s emotional resilience, finances, and confidence in the process. Wanting a thorough second opinion in that situation is entirely reasonable.

However, a second opinion is only as good as the objective data behind it. Consulting a new fertility specialist without your previous medical records makes it harder to understand what happened in the last cycle and may lead to avoidable repetition. Every cycle generates clinical information; retrieving the records held about your care allows those details to inform the next step.

Video: Second Opinion in IVF and Retrieving Your Medical File

Second Opinion in IVF — Getting Your Medical File Back — Dr Senai Aksoy

(Note: This video features English and Arabic audio tracks and subtitles. You can select your preferred language in the YouTube player settings.)

What is the modern definition of Recurrent Implantation Failure (RIF)?

For decades, recurrent implantation failure (RIF) was often described using fixed thresholds, such as three consecutive failed transfers or ten good-quality embryos transferred without success. Those numbers are not a universal rule for every patient.

The European Society of Human Reproduction and Embryology (ESHRE) recommends individualising the assessment. The American Society for Reproductive Medicine (ASRM) defines RIF using the estimated number of good-quality blastocysts needed to reach a 95% cumulative chance of a positive pregnancy test. The evidence base remains imperfect, and there is no single threshold that applies to everyone.

Instead of merely counting attempts, clinicians review the patient’s individual profile: age, ovarian reserve, embryo stage and morphology, whether embryos were genetically tested, the uterine cavity, and the details of each transfer. A negative transfer may justify a more focused review earlier when the outcome is clearly different from the expected prognosis, but that does not automatically mean that extensive testing is needed.

For patients whose prognosis is naturally lower because of age, ovarian response, or other factors, the same approach helps avoid expensive or invasive investigations after a single result that may still be compatible with the expected range.

Which uterine and inflammatory factors may need review?

Before repeating an IVF protocol, the uterine cavity and the previous transfer history should be reviewed in context. Further assessment is most useful when the history, imaging, or previous cycle details raise a specific question:

What can an embryology report tell you about a previous cycle?

When reviewing a previous cycle, the embryology report provides useful context about when development slowed:

Which add-on tests and treatments are supported by evidence?

Patients facing IVF failure are frequently offered numerous commercial “add-ons.” The options below should not be read as a universal treatment ladder. ASRM and ESHRE both emphasise targeted evaluation after a detailed review, while the Almohammadi et al. umbrella review also warns that the underlying evidence is heterogeneous and often methodologically weak:

Intervention / TestEvidence TierClinical Reality
Cavity assessment and treatment of a confirmed abnormality🟡 TargetedHysteroscopy or other imaging may be appropriate when recurrent implantation failure is suspected or a cavity abnormality is suspected; treatment depends on the finding.
Parental karyotyping🟡 Selected casesMay be considered for structural chromosomal rearrangements after a clinical review; genetic counselling is needed if a rearrangement is found.
PGT-A (aneuploidy testing)🟡 Shared decisionMay help investigate embryo ploidy in selected patients with untested embryos, but ASRM reports no evidence that it increases live birth in RIF.
ERA testing and endometrial scratching🔴 Not routineEvidence is insufficient for routine ERA use, and endometrial injury has not shown a consistent live-birth benefit.
Empirical immunotherapies (intralipids, IVIG)🔴 Not routineEvidence is insufficient for routine use, and potential harms and costs should be discussed.

Understanding why an IVF cycle did not succeed requires access to the records held about your care.

In Turkey, Article 16 of the Patient Rights Regulation (Hasta Hakları Yönetmeliği) allows a patient, or an authorised representative, to inspect the file and records containing information about the patient’s health and obtain a copy. For a second opinion, you can ask the centre for relevant records such as:

  1. Stimulation monitoring charts and prescribed gonadotrophin doses.
  2. Oocyte retrieval records, including the number and maturity of oocytes where recorded.
  3. Embryology culture reports, including the fertilisation method, developmental observations, and blastocyst grades.
  4. Embryo-transfer notes, including the catheter, ultrasound guidance, and any documented technical difficulty.

The regulation does not set out every document format or response time on this page. A written request can help create a clear record of what you asked for. If the centre does not respond, ask for the reason in writing and seek advice from the relevant patient-rights authority or a qualified lawyer. Rules may differ when treatment took place outside Turkey.

Dr. Aksoy’s Approach: Why We Never Start from a Blank Page

Dr. Aksoy’s Clinical Perspective

“When a couple consults me for a second opinion, the first question I ask is not simply ‘how many eggs did you have?’ but where did the cycle encounter its biological bottleneck?

Did the gonadotrophin dose match the antral follicle count? What was the mature oocyte ratio? Was there a sharp drop at fertilization? Did embryo development stop at Day 3 or on the way to Day 5? Was the embryo transfer smooth or technically difficult? Were luteal progesterone levels verified?

These granular details may change my recommendation—for example, by prompting an adjustment to the stimulation protocol or trigger timing, the use of ICSI when clinically indicated, or an embryo-banking strategy.

A common misconception is that every failed transfer means ‘my uterus rejected the embryo.’ Unless embryos were genetically tested, maternal-age-related chromosomal aneuploidy is an important population-level explanation, but it is not the only possible explanation for an individual transfer.

Before starting a new cycle, I begin by reviewing the prior embryology and transfer records. Depending on the history, an updated pelvic ultrasound, cavity assessment, or review of sperm parameters may be appropriate. I avoid subjecting patients to unproven immune panels or generic add-on packages.

Our objective is never to add random treatments, but to identify which part of the previous attempt needs review and adjust only what the evidence and clinical context support.”

Dr. Senai Aksoy

Frequently Asked Questions

Can I legally request the relevant embryology records from my previous clinic?

Usually, you can request records containing information about your health under Article 16 of Turkey’s Patient Rights Regulation, including relevant stimulation, embryology, and transfer records held by the centre. The exact documents and procedure may depend on how the records are kept and where the treatment took place.

Why do morphologically excellent embryos fail to implant?

Embryo grading (such as 4AA or 5AB) evaluates visual physical appearance under a microscope. It does not assess chromosomal structure. Even top-grade embryos may carry numerical chromosomal abnormalities (aneuploidy), which may reduce implantation potential or be associated with early developmental arrest.

What might be evaluated before embarking on another IVF cycle?

There is no single mandatory panel for everyone. Depending on the history and previous records, review may include the stimulation and embryology logs, an updated ultrasound, assessment of the uterine cavity when a specific indication is present, and an updated semen analysis when relevant.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.